NCT03729245: A trial that was reported late by Nektar Therapeutics
This trial has reported, although it was 41 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03729245 |
|---|---|
| Title | A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 18, 2018 |
| Completion date | Jan. 7, 2022 |
| Required reporting date | Jan. 7, 2023, midnight |
| Actual reporting date | Feb. 17, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 41 |